The Transhuman Daily · EP.017 · Wednesday 18 November 2026
TRIAL AND ERROR.
Trial and error: an Alzheimer's pill missed overall but helped one group, OpenAI rated Astra High for helping improve AI, and a leukaemia vaccine stretched survival to two years (company data).
The Transhuman Daily
TRIAL AND ERROR.
The Transhuman Daily
SUPER INTELLIGENCE
The Transhuman Daily
SUPER LONGEVITY
The Transhuman Daily
SUPER WELLBEING
The Transhuman Daily
THE CATCH
The Transhuman Daily
THE FRONTIER
Transcript
Read the narration
Welcome to the Transhuman Daily, Wednesday edition.
Here are the last 24 hours in transhumanism, in 3 minutes.
Trial and error! An Alzheimer's pill missed overall, but slowed decline by nearly a third in one group.
And in a ten-person trial, MDMA therapy cut veterans' PTSD from severe to mild.
OpenAI's new Astra is its first public mode l rated high for helping improve AI itself.
Google's Gemini Tasks, an agent that calls businesses, books appointments and shops, is now free.
Microsoft says its new MAI Code 2 nearly matches rivals at a fraction of the cost.
And grant pitches written with more AI help stuck closer to ideas already funded, a study found.
On to longevity.
A leukaemia vaccine lifted typical survival from 15 months to two years, its maker says.
And a light and sound headset for Alzheimer's missed too, though milder cases hinted at a benefit.
In a dish, Yamanaka's team found turning back a cell's clock doesn't always make it work better.
Closer to home, a Wollongong-led team is building corneas in the lab, with first tests due next year.
On to wellbeing. In a small trial, psilocybin eased the loss of joy in hard-to-treat depression.
And an AI that watches how you walk spotted links to sleep, mood and even liver health.
Now, the catch.
Interpol and the UN warn brain-reading tests in police interviews aren't proven to work.
And OpenAI's own tests found Astra kept quiet about known problems twice as often as before.
On Saturday, China's all-electric, 19-seat airliner flew with a crew for the first time.
Boston Dynamics' Atlas humanoid heads into chip factories for testing next year, its first beyond carmakers.
Oh, and physicists found a way to put error bars on quantum machines too big to check.
Some trials miss, some win, and each one moves us forward. That's trial and error.
Every day, the curve gets a little steeper.
Somehow, the future keeps landing early.
That's one day of news. Imagine what a year looks like.
That's the Transhuman Daily for today.
Stay well. Same time tomorrow?
Want more? Meet us in North Sydney on November 27.
Good to know
Window: the 24 hours to 06:13 AEDT, Wed 18 Nov 2026. Evidence: the AriBio, SELLAS and Cognito results are company topline data, not peer reviewed; OpenAI's and Microsoft's figures are company claims; the reprogramming study is a preprint in cells; the MDMA (10 people) and psilocybin (20 people) trials are small; the gait study shows links, not a diagnosis. This week: AriBio's AR1001 results (CTAD, 16 Nov, released just before the window), COMAC's first crewed CE-25A flight (14 Nov) and the quantum error-bars study (Physical Review X, 15 Nov). Screenshots are the publishers' public pages as captured on 18 Nov 2026; copyright remains with the publishers. Every headline links to its source. The narrator is an AI voice; the visuals and music are generated for each episode. Nothing here is medical or financial advice.
Membership
Join the movement
Membership is how the movement grows. It keeps our meetups free and open to everyone, and it puts you in the room with the people building a longer, healthier, smarter future.
- Keep the meetups free Your support keeps every monthly meetup free and open, and brings great speakers to Sydney.
- Member deep-dives Guided tutorials and deep-dives on AI, longevity, neurotech and more, so you learn by doing.
- Meet the builders Founders, researchers, investors and biohackers working on transhuman technology.
- Hear it first New events, projects and opportunities across our network, before anyone else.
Not ready yet? Come to a free meetup first.
